Lilly's new oral pill, Orforglipron, has shown promising results in reducing weight and improving blood sugar levels in diabetes patients. With nearly 4% rise in shares, the drug is on track for FDA approval.
A groundbreaking study shows that bariatric surgery leads to five times more weight loss than GLP-1 drugs like semaglutide. Discover why surgery remains the gold standard in obesity treatment.
A new regulator confirmation links Ozempic to a rare eye condition, NAION, affecting diabetes patients. This revelation raises concerns about potential blindness risks associated with semaglutide. Discover the implications for users.
Recent clinical trials show that GLP-1 weight loss medications like Zepbound are more effective for women than men, prompting researchers to explore the biological and societal reasons behind this phenomenon.
In a groundbreaking clinical trial, Mounjaro proves to be nearly 50% more effective than Ozempic. This article explores the implications of this major breakthrough in weight loss treatments.
A groundbreaking trial reveals that Mounjaro is more effective than Wegovy for weight loss, achieving a 20% reduction over 72 weeks compared to Wegovy's 14%. Discover the implications for obesity treatment!
A groundbreaking study reveals semaglutide, already known for weight loss and diabetes treatment, is effective for fatty liver disease, benefiting two-thirds of participants in a recent trial. This could revolutionize treatment options!
Eli Lilly introduces discounted higher doses of the weight loss drug Zepbound in a move to make the treatment more accessible to uninsured patients and address the growing demand for obesity treatments.
